Literature DB >> 2880378

[11 cases of neuropathy induced by almitrine, of which one had optic neuropathy].

M Blondel, G Arnott, S Defoort, B Bouchez, P Persuy, M Masingue, J C Hache, I Krivosic.   

Abstract

The only etiologic factor retained in 11 patients with sensory or sensory-motor neuropathy was almitrine therapy. In one patient there was in addition an optic neuropathy. The reduction in visual acuity in this patient coincided with the onset of the sensory-motor neuropathy of lower limbs after treatment with 100 mg/day of almitrine over a 2-year period. No other metabolic, inflammatory, toxic, vascular or immunologic cause was found. There was a moderate chronic respiratory insufficiency. Visual recuperation started one month after the arrest of almitrine treatment and was satisfactory 7 months later. The other 10 patients had neuropathy of limbs without visual disorders. Neuromuscular biopsy in one case showed lesions to be of the axonal type.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2880378

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  4 in total

1.  Almitrine-induced peripheral neuropathy and weight loss.

Authors:  R Gherardi; L Bélec; F Louarn
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

2.  Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.

Authors:  L Belec; D Larrey; H De Cremoux; M Tinel; F Louarn; D Pessayre; R Gherardi
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

3.  Almitrine neuropathy. A nerve biopsy study of 8 cases.

Authors:  R Gherardi; M Baudrimont; F Gray; F Louarn
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

4.  Peripheral neuropathies during treatment with almitrine: report of 46 cases.

Authors:  P Bouche; L Lacomblez; J M Leger; M P Chaunu; H Ratinahirana; P Brunet; J J Hauw; H P Cathala; D Laplane
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.